Figure 1.

Systemic administration of the CB1/2 receptor agonist, WIN 55,212-2 (WIN) attenuates audiogenic seizures in genetically epilepsy-prone rats (GEPRs). (A) Schematic of the testing scheme; animals were tested with a baseline test session before a vehicle-treated session. On a separate day, animals were tested on a baseline session and then with one of three doses of WIN. The testing order was counterbalanced across subjects. (B) Against audiogenic seizures (AGS) scores showing baseline sessions and comparing vehicle (left) and 1 mg/kg WIN (right). (C) AGS scores showing baseline sessions and comparing vehicle (left) and 1.5 mg/kg WIN (right). (D) AGS scores showing baseline sessions and comparing vehicle (left) and 2 mg/kg (right). Bars indicate median and interquartile range, symbols show individual subjects. *p < 0.05, according to Friedman test followed by Dunn’s post hoc test.